Roivant Sciences

Edit info

Founded: 2014

Location: New York, NY

Employee range: 200 - 500

Clinical stage: COM

Therapy area: Psoriasis

Drug types: NEU, END, GEN, ONC, DRM, IMM, INF, RAR, HEM, OPH, MUS, GI

Lead product: Vtama

Funding: $200M stock Feb 2023; $200M Nov 2018

roivant.com

linkedin.com

job board

Drug notes:

Also Clin3 atopic dermatitis; pipeline: https://www.roivant.com/pipeline

About:

Roivant Sciences is focusing on the discovery, development and commercialization of transformative medicines. To accelerate the commercialization of medicines, Roivant builds nimble subsidiaries they call “Vants” to develop novel technologies. Since inception, Roivant’s Vants have conducted 10 positive Phase 3 clinical trials and launched VTAMA®, a topical cream for the treatment of plaque psoriasis in adults. However, Roivant is advancing a broad and differentiated pipeline of investigational drugs across numerous therapeutic areas including immunology, oncology, hematology and dermatology.

Senior Analyst, Real-World Evidence (RWE)Senior Analyst, Real-World Evi...

Roivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States|6 days ago

Apply

Accounting Operations SpecialistAccounting Operations Speciali...

Roivant Sciences, Inc., 1 Pennsylvania Plaza, 54th floor, New York, NY 10119, United States|26 days ago

Apply

Founding Engineer, Roivant HealthFounding Engineer, Roivant Hea...